Quality · Access · Hope
Countries

🇯🇵 Country Profile

Japan

Fast-growing pharmaceutical trade with Japan

🇯🇵 $134M
Dual-source profile. Both series show HS Chapter 30 (finished pharmaceutical products) aligned to calendar year (Jan–Dec). Japan Customs records what Japan imports from India. DGCIS records what India exports to Japan. Category and product detail from DGCIS.
$134M
Scale
Japan's healthcare system receives $134M in Indian pharmaceutical products each year — affordable, quality medicine.
52%
Medicine
A diverse pharmaceutical mix: medicine ingredients, medicines, and traditional & herbal each contributing significantly.
3.1×
Trajectory
Rapid expansion: Japan's imports of Indian pharmaceutical products have grown 3.1× over the past decade, from $42.7M to $134M.
Context
Part of India's pharmaceutical supply network across Asia-Pacific.
✦
Impact
Indian pharmaceutical companies have both exported to and invested directly in Japan — building trade and operational presence.
Export Trend Japan Customs CY DGCIS Ch.30
Beyond Finished Medicines DGCIS CY 2014–2025

Non-Chapter-30 pharma categories from DGCIS (487-code basket)

Category Mix — FY 2025–26 DGCIS
Medicine Ingredients $127M (51.7%) Medicines $110M (44.5%) Traditional & Herbal $5.8M (2.3%) Surgical & Hospital Supplies $3.1M (1.3%) Vaccines $0.51M (0.2%)
Top Products — FY 2025–26 DGCIS
Active Pharmaceutical Ingredients DGCIS India-side

India also supplied $120M in active pharmaceutical ingredients and bulk drugs to Japan in 2025 (India-reported, DGCIS).

Indian Pharma Investment in Japan Source: RBI ODI Data

Total RBI-approved ODI commitments by Indian pharmaceutical companies into Japan: $2.3M across 6 filings (2012-2025).

Global Pharma Thrives in India Source: OPPI / Annual Reports

The relationship flows both ways. Japanese pharmaceutical companies are among the largest investors in India's health ecosystem — operating manufacturing plants, R&D centres, and clinical trial networks across the country.

Takeda
$31B global revenue
50,000 employees
Entyvio (Gastroenterology) · TAKHZYRO (Rare Diseases) · ALUNBRIG (Oncology)
Otsuka
$28B global revenue
35,338 employees
Samsca/JINARC (Nephrology) · REXULTI (Psychiatry) · ABILIFY MAINTENA (Psychiatry)
Astellas
$23B global revenue
XTANDI (Oncology) · PROGRAF (Immunology) · PADCEV (Oncology)
Eisai
$9B global revenue
Lenvima (Oncology) · Aricept (Neurology) · Halaven (Oncology)